Synopsis
Choose and reassess fluids, analgesia and nutritional support in acute pancreatitis, with explicit patient selection, measurable response and prompt adjustment when treatment causes harm.
- Use lactated Ringer’s for assessed fluid need, usually a moderate approach with repeated perfusion and overload checks; do not prescribe aggressive hydration to prevent necrosis.
- An early adult trial example is 1.5 mL/kg/hour, with a 10 mL/kg bolus over two hours only for hypovolaemia; shock and major cardiorenal disease need an individual plan.
- Provide prompt analgesia using the selected product’s safety limits. If moderate or severe disease prevents adequate oral intake, start enteral nutrition within 72 hours of presentation; use parenteral nutrition when enteral feeding fails or is contraindicated.
Key red flags
Breathlessness, new crackles or increasing oxygen requirement during intravenous fluids.
Persistent hypotension, confusion or falling urine output despite assessed treatment.
Excessive sedation, slowing respiration or difficulty waking after opioid administration.
Look for new breathlessness, crackles, peripheral oedema, raised venous pressure and a rising oxygen requirement, and interpret the cumulative balance. Overload and inflammatory lung injury can coexist. Slow or stop an infusion when overload is suspected while obtaining urgent assessment; a concurrent low urine output does not automatically justify continuing the same prescription.
Investigation priorities
Link each infusion decision to observed perfusion and respiratory effects.
Management branches
A constructed 70 kg adult example has early pancreatitis, hypovolaemia and no shock or cardiorenal limitation.
- A 38-year-old man with hypertriglyceridaemia-associated pancreatitis has dry mucosa, haematocrit 47% and urine output 20 mL/hour. He is alert, has blood pressure 106/68 mmHg and normal renal function, without overload, heart failure, cirrhosis, ileus or biliary/renal tract spasm. The team gives lactated Ringer’s 700 mL intravenously over two hours, then 105 mL/hour, with examination during treatment and a planned early reassessment.
- Vomiting prevents oral analgesia. He receives ALTAN paracetamol 1 g/100 mL intravenously over at least 15 minutes, limited to 3 g/day while dehydrated. For continuing severe pain, the trained pain service cautiously selects hameln morphine 1 mg/mL PCA after its safety checks: a 2 mg/2 mL loading infusion over five minutes, then 1 mg/1 mL demands with a ten-minute lockout and no background infusion. Pain, sedation, respiration and pressure are monitored. At the three-hour review, urine output has risen to 45 mL/hour and pain has fallen to 3/10, with clear lungs, normal alertness and a respiratory rate of 16/min.
Key medicines
ALTAN paracetamol 10 mg/mL solution for infusionFor adults over 50 kg: 1 g in 100 mL intravenously over at least 15 minutes, at least four hours between doses and no more than four doses in 24 hours. Maximum 4 g/day only without hepatic risk; maximum 3 g/day with dehydration, chronic malnutrition, chronic alcohol exposure or hepatocellular insufficiency. The dehydrated case uses 1 g every eight hours, maximum 3 g/day. At creatinine clearance 30 mL/min or below, leave at least six hours between doses. For weight over 33 to 50 kg, use 15 mg/kg per dose and no more than 60 mg/kg/day, capped at 3 g/day.Check weight and total paracetamol from every product; prescribe both milligrams and millilitres. Contraindicated with paracetamol/propacetamol or excipient hypersensitivity and severe hepatocellular insufficiency. Use the lower daily ceiling for the listed risk factors, reassess daily and switch to oral treatment as soon as possible. Review liver disease, renal impairment and interacting medicines: probenecid may require dose reduction, repeated regular dosing can affect warfarin control, and flucloxacillin plus sepsis, renal impairment or malnutrition increases the risk of high-anion-gap acidosis. Stop paracetamol and investigate if that acidosis is suspected. Pregnancy requires the lowest effective dose for the shortest necessary time; breastfeeding is compatible. Account for the infusion’s fluid, sodium and glucose where relevant.
Hameln morphine sulfate 1 mg/mL for intravenous PCATrained-service PCA example for an assessed opioid-naive adult: give 2 mg in 2 mL intravenously over five minutes as a loading dose, then 1 mg in 1 mL per patient demand with a ten-minute lockout and no background infusion. The exact product allows a usual loading range of 1–10 mg, maximum 15 mg, over four to five minutes and an initial 1 mg demand with a five- to ten-minute lockout. Use undiluted 1 mg/mL solution. Individualise under the pain service, monitor the early response and review the need daily; use for the shortest necessary period and plan reduction/discontinuation.Current European guidance advises cautious, individually selected PCA in pancreatitis; evidence is limited and does not establish superiority over other analgesic delivery. Product 5008 is not interchangeable with hameln product 6426, which lists pancreatitis as a contraindication. For 5008, do not use with opioid/excipient allergy, respiratory depression or obstructive airways disease, head injury or raised intracranial pressure, coma, convulsive disorders, ulcerative colitis or ileus risk, biliary/renal tract spasm, acute alcoholism, phaeochromocytoma, GFR below 20 mL/min, severe/acute liver failure or MAOI exposure within two weeks. Reduce doses for older or debilitated patients and noncontraindicated renal/chronic hepatic disease. Pregnancy and breastfeeding use is not recommended. Monitor pain, sedation, respiration, pressure and bowel function; stop delivery and seek urgent help for excessive sedation or respiratory depression. Morphine can provoke sphincter-of-Oddi spasm and aggravate pancreatic/biliary symptoms. Avoid concurrent sedatives unless necessary; if used, minimise doses/duration and intensify monitoring. Explain dependence risk, review the stop plan and taper when continued exposure makes withdrawal a concern.